| 52-Week High | 13.66 |
|---|---|
| Last Price | 9.12 |
| Fibonacci 50% | 8.98 |
| Fibonacci 38.2% | 7.88 |
| 52-Week Low | 4.30 |
Who owns Flexion Therapeutics stock?
Company insiders that own Flexion Therapeutics stock include Adam Muzikant, Christina Willwerth, David Arkowitz, Mark S Levine, Mark Stejbach, Melissa Layman and Michael D Clayman. View institutional ownership trends for Flexion Therapeutics. Which major investors are selling Flexion Therapeutics stock?
What is the upside for Flexion Therapeutics'share price?
On average, they expect Flexion Therapeutics' share price to reach $25.50 in the next twelve months. This suggests a possible upside of 82.3% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.
What are the price targets for Flexion Therapeutics'shares?
9 brokers have issued 12 month price objectives for Flexion Therapeutics' shares. Their forecasts range from $6.00 to $18.00. On average, they anticipate Flexion Therapeutics' share price to reach $12.43 in the next twelve months. This suggests a possible upside of 36.3% from the stock's current price.
Where can I buy shares of flxn?
Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is flexion stock a good buy?
Flexion Therapeutics has 17.00% upside potential, based on the analysts' average price target. Can I see which stocks the top-ranking analysts are rating? Yes, go to the Analysts' Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
What happened flexion stock?
Flexion (ticker: FLXN) is being acquired by New Jersey-based Pacira BioSciences (PCRX) in a deal valued at around $427.5 million. Adamas (ADMS) is set to be acquired by Supernus Pharmaceuticals (SUPN) for approximately $400 million. Flexion and Pacira both specialize in developing non-opioid pain management solutions.
Is FLXN stock a buy?
The Cash/Price ratio is calculated as cash and marketable securities per share divided by the stock price....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Who bought flexion?
Pacira BioSciences, a biopharmaceutical company focused on non-opioid pain management, announced that it had acquired Flexion Therapeutics, a company specializing in treatments for musculoskeletal conditions, on Oct.
Should I buy or sell Flexion Therapeutics stock right now?
7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 7 hold...
What is Flexion Therapeutics' stock price forecast for 2022?
7 brokerages have issued twelve-month target prices for Flexion Therapeutics' stock. Their forecasts range from $6.00 to $18.00. On average, they p...
How were Flexion Therapeutics' earnings last quarter?
Flexion Therapeutics, Inc. (NASDAQ:FLXN) released its quarterly earnings results on Wednesday, May, 12th. The specialty pharmaceutical company repo...
Who are Flexion Therapeutics' key executives?
Flexion Therapeutics' management team includes the following people: Michael D. Clayman , President, Chief Executive Officer & Director Fred Dris...
What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?
46 employees have rated Flexion Therapeutics CEO Mike Clayman, MD on Glassdoor.com . Mike Clayman, MD has an approval rating of 85% among Flexion...
Who are some of Flexion Therapeutics' key competitors?
Some companies that are related to Flexion Therapeutics include ChemoCentryx (CCXI) , HUTCHMED (HCM) , Aurinia Pharmaceuticals (AUPH) , Arcus B...
What other stocks do shareholders of Flexion Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therape...
What is Flexion Therapeutics' stock symbol?
Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."
Who are Flexion Therapeutics' major shareholders?
Flexion Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading L...
Barchart Technical Opinion
Business Summary
The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.
Flexion Therapeutics
Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United...
About FLXN
Some stock charts might currently not be supported. To try again, please refresh this page.
